V-Bio Ventures

We are a life sciences fund investing throughout Europe in start-up and early-stage companies with high growth potential. Our articles cover investment-related topics in life sciences, including innovation trends, the latest business themes and exciting updates on our portfolio companies.

V-Bio Ventures

July 18, 2019

How do we reduce the high cost of clinical trials?

Drug development is an exorbitantly expensive endeavor. A large expense factor for developing a new therapy is the high cost of conducting clinical trials. Why are clinical trials so insanely expensive to run? And what can be done to increase the affordability of these trials?

June 27, 2019

Betting big on blood screens for early cancer detection

for V-Bio Ventures

May 29, 2019

OCTIMET Oncology tackling cancer with a new captain at the helm

for V-Bio Ventures

April 16, 2019

Cultured meat, plant-based patties and bug burgers: VCs are backing protein alternatives

When it comes to food, our key sources of nutrition haven’t changed much in the last ten thousand years. Though hyped-up food trends and diets come and go, our ancestors established the status quo for our primary protein sources a long time ago: animal products, like dairy, eggs and meat, have been the staples ever since we switched from hunters to farmers. However, with rising global populations driving sky-high demand for animal products, is it time for another food revolution?

March 19, 2019

Closing the gender gap in biotech funding

Companies with a good gender balance consistently outperform those with only men in their management teams. Yet despite this, start-ups with female founders and management team members are consistently underfunded compared to all male companies. Could it be that the gender gap in funding has its roots in the gender disparity in the financing firms themselves?

February 19, 2019

Life after a PhD: alternatives to academia

for V-Bio Ventures

January 22, 2019

Are we spending too much money on cancer drugs?

for V-Bio Ventures

November 20, 2018

Why start-ups can become mega companies in the pharma sector

for V-Bio Ventures

November 15, 2018

V-Bio Ventures leads Camel-IDS EUR 37m Series A financing

for V-Bio Ventures

15 November 2018, Ghent (Belgium) - V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceuticals

October 30, 2018

Are tech investments under threat by anti-science sentiments?

for V-Bio Ventures

October 2, 2018

Bringing clinical trials into the home

for V-Bio Ventures

September 18, 2018

V-Bio Ventures participates in 22.5 million euros series B financing round of Horama

for V-Bio Ventures

Ghent (Belgium), September 18th, 2018 - The Belgian life sciences venture fund V-Bio Ventures (www.v-bio.ventures) today announces that it joins the “Series B” financing round of Horama (www.horama.fr). Horama is a French biotech company based in Paris and Nantes, which specialises in gene therapy for the treatment of rare genetic diseases in ophthalmology. Willem Broekaert, Managing Partner at V-Bio Ventures, will be appointed to the Horama Board.